Publications by authors named "A Harbin"
Article Synopsis
- The study focuses on developing VHL-binding PROTACs that specifically target and degrade the BRM protein in lung cancer cells.
- These PROTACs show significant selectivity, degrading BRM up to 100 times more than its similar cousin, BRG1, and hinder the growth of BRG1-mutant NSCLC cells that rely on BRM.
- Further testing in animal models demonstrated that achieving over 95% BRM degradation is crucial for effective antitumor responses, linking BRM activity to tumor growth regulation.
Article Synopsis
- Targeted protein degradation (TPD) is highlighted as a new therapeutic strategy using PROTAC technology to selectively degrade proteins in cells.
- Researchers discovered small-molecule ligands that specifically target the E3 ligase KLHDC2, expanding the options available for TPD.
- The study reveals how the KLHDC2 E3 ligase forms a dynamic tetrameric structure, which can be influenced by the interaction with substrates and ligands, enhancing our understanding of its functioning and potential applications.
We compared outcomes of robot-assisted simple prostatectomy (RASP) in patients with and without a history of prior prostate surgery for management of symptomatic benign prostatic hyperplasia (BPH). We retrospectively reviewed our multi-institutional database for all consecutive patients who underwent RASP between May 2013 and January 2021. Postoperatively, urinary function was assessed using the American Urological Association symptom score (AUASS) and quality of life (QOL) score.
View Article and Find Full Text PDFIn the development of new vaccines, many trials use age de-escalation: after establishing safety and efficacy in adult populations, progressively younger cohorts are enrolled and studied. Age de-escalation promotes many values. The responsibility to protect children from potential risks of experimental vaccines is significant, not only given increased risks of adverse effects but also because parents and medical professionals have a moral responsibility to protect children from harms associated with novel, uncertain interventions.
View Article and Find Full Text PDFArticle Synopsis
- Scientists studied a protein called SMARCA4 that often has mutations in cancer and found that cancer cells rely on another protein called SMARCA2 when SMARCA4 is broken.
- They created a special molecule called A947 that can specifically target and get rid of SMARCA2 without affecting other proteins.
- Tests showed that A947 works well against cancer cells with broken SMARCA4, offering hope for new treatments for patients with this kind of cancer.